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In our continuing efforts to develop mass spectrometry-based methods for transthyretin (TTR)
variant detection and characterization, we have sought to use matrix-assisted laser desorp-
tion/ionization (MALDI) bioreactive probes incorporating immobilized trypsin for screening
purposes. These devices show good diagnostic potential as a clinical screening tool to detect
amino acid substitutions in TTR. MALDI probes allow the on-probe generation of tryptic
digests. The subsequent mass analysis of the on-probe digest yields the peptide map. The
inherent advantages of this method include considerably reduced digestion times (minutes vs.
hours), absence of autolysis products, minimized sample handling, and hence minimal sample
loss. A further advantage is that the opportunity for loss of hydrophobic peptides is reduced
because no sample transfer occurs. The method can be applied as a preliminary screen for TTR
variants where TTR is isolated from patient serum through immunoprecipitation. This method
should also be applicable to other proteins and suitable for automation. (J Am Soc Mass
Spectrom 2000, 11, 172–175) © 2000 American Society for Mass Spectrometry
The development of methods to detect and char-acterize protein variants has been sustained bycontinuing interest in inherited disease. In the last
decade, mass spectrometry has been remarkably suc-
cessful in the analysis of protein variants, particularly
those having single amino acid substitutions, most
notably in the case of hemoglobins [1]. We have sought
to develop and apply mass spectrometry techniques to
the detection and characterization of transthyretin
(TTR) variants. We have recently presented a systematic
approach based on high-performance liquid chroma-
tography/electrospray ionization mass spectrometry
(HPLC/ESIMS) and matrix-assisted laser desorption/
ionization mass spectrometry (MALDIMS) to detect
and characterize unknown TTR variants [2]. In our
continuing efforts to develop mass spectrometry based
methods for TTR variant detection and characterization,
the use MALDI bioreactive probes [3, 4] incorporating
immobilized trypsin for screening selected groups of
samples was investigated. The inherent advantages of
this method include considerably reduced digestion
times (minutes vs. hours), absence of autolysis prod-
ucts, minimization of sample handling, and sample
loss. With on-probe digestion, hydrophobic peptides
are less likely to be lost because no sample transfer
occurs. The method also lends itself to automation.
Transthyretin amyloidosis (ATTR) is a hereditary
degenerative disease characterized by proteinaceous
deposits. These deposits hinder organ functions and
ultimately lead to their failure(s) and death. The disease
is closely linked with single amino acid substitutions in
the plasma protein transthyretin (TTR) [5]. TTR consists
of 127 amino acids and is homotetrameric in its native
state. The main hypothesis for the pathogenesis of
ATTR is linked to the stability of the tetramer and how
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single amino acid substitutions could alter it, presum-
ably causing aggregation or polymerization of TTR
monomers to form amyloid fibrils. There are over 80
known mutations of TTR, a minority being nonamyloi-
dogenic. The accelerating rate of TTR variant discovery
strongly suggests that more variants remain to be
characterized. In the U.S., the prevalence of the variant
TTR genes may be as high as 1 in 100,000 [5]. The
clinical profiles (phenotypes) of ATTR may be very
similar to other types of amyloidoses but the treatments
are different and incompatible. Hence, correct diagnosis
is crucial. In ATTR, a definitive diagnosis relies on the
detection and characterization of TTR mutants. MALDI
bioreactive probes can be used to generate quick and
efficient tryptic digests of TTR that can be mass ana-
lyzed readily. The results we have obtained indicate
that these devices show good diagnostic potential as a
clinical tool to screen for amyloidogenic amino acid
substitutions in TTR among selected populations. Our
initial report [6] and a simultaneous contribution ad-
dressing the potential of bioreactive probes for hemo-
globin variant analysis [7] represent the first clinical
applications of these devices.
Experimental
MALDI Probe Modifications
The “on-probe” digestion was performed on small
metal disks whose gold-covered surface was derivat-
ized with immobilized trypsin. The bioreactive disks
were purchased from Intrinsic Bioprobes (Tempe, AZ).
These disks were then mounted on a modified Vision
2000 MALDI probe (Figure 1) for MALDI-TOFMS anal-
ysis. The disks were solidly held in place by a magnet
underneath the sample stage. This required that the
disk be handled with nonmagnetic steel tweezers. Disks
are low cost and disposable, hence there is no risk of
carryover from sample to sample.
Method
TTR was isolated from patient serum through immu-
noprecipitation. This was achieved by mixing an equal
amount (10–100 mL) of patient serum and rabbit anti-
serum (DAKO A/S, Glostrup, Denmark). The protein
was then separated from the antibody by reversed
phase HPLC (C4 Vydac 4.6 3 250 mm). This purifica-
tion step also denatures the protein. The fraction con-
taining TTR was dried down and subsequently dis-
solved in 20–50 mL of 15 mM NH4HCO3 buffer and an
aliquot (2 mL) was applied to the bioreactive probe. The
digestion was allowed to proceed in a humid enclave
for 10–30 min at 45 °C. The addition of 2 mL of DHB
with 1% TFA stopped the digestion. MALDI mass
spectra were obtained with a Finnigan MAT Vision
2000 (Thermo BioAnalysis, Santa Fe, NM) time-of-flight
mass spectrometer equipped with a reflectron. The
nitrogen laser (Laser Science, Franklin, MA) had 3 ns
pulse width at 337 nm. All data were obtained in the
reflectron mode at 5 kV acceleration voltage, with 6 kV
postacceleration applied before the detector. Because
the detector is an electron multiplier, no deflection of
low mass ions was needed or employed.
Results and Discussion
MALDI bioreactive probes appear to be devices well
suited for TTR variant detection. The use of MALDI
probes derivatized with immobilized trypsin allows the
rapid generation of protein digests from small quanti-
ties of sample (after overnight immunoprecipitation), in
a format ready for mass analysis. Figure 2a shows the
MALDI mass spectrum of the on-probe digestion of the
TTR obtained from the serum of a non-ATTR individ-
ual. The majority of tryptic peptides corresponding to
incomplete cleavages observed in the MALDI mass
map (Table 1) are consistent with those reported in the
literature [8, 9] where “classical” digestion conditions
were used to ensure as complete a digestion as possible.
Using “long” (15 min) on-probe digestion time to en-
sure complete digestion also provides a highly repro-
ducible peptide map and hence easy comparison
among samples where detection of a variant peptide is
relatively simple.
Figure 2b shows the MALDI mass spectrum of the
15-min on-probe digestion of the TTR obtained from the
serum of an ATTR patient with a Val30 3 Met substi-
tution. The mutant peptide can readily be observed at
m/z 1397.8, corresponding to the 132 Da mass shift
resulting from the Val3Met substitution. The presence
of a methionine residue in the mutant peptide sequence
is confirmed by an additional peak 116 Da from the
mutant peptide. This peak is indicative of the oxidation
of the methionine thioether.
It is evident that the use of bioreactive probes to
obtain molecular weight profiles of the tryptic peptides
does not allow as complete characterization of TTR
Figure 1. Schematic drawing of the modified Vision 2000
MALDI probe.
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mutants as our protocols which include tandem mass
spectrometry (MS/MS) and postsource decay (PSD)
measurements [2]. However, analyses using bioreactive
probes are rapid and do present significant advantages
over simple methods for molecular weight determina-
tions on the intact protein(s) [10, 11]:
• The mass shift between the variant and wild type is
determined with greater accuracy than ESIMS of
whole protein and therefore a smaller number of
amino acid substitutions needs to be considered.
• Mass shifts between variant and wild type smaller
than 10 Da can be measured.
• The location of the mutation is specified within a
well-defined region of the sequence.
The coverage obtained by on-probe digestion is favor-
ably comparable to solution digestion (see Table 1) and
can probably be improved by optimization of experi-
mental parameters. Preliminary results indicate that
sequence coverage of ’83% can routinely be obtained
using this method. This sequence coverage encom-
passes 90% of known amyloidogenic TTR variants.
Access to the N-terminus sequence (positions 1–21,
tryptic peptides 1–3) could be improved by using
shorter digestion times to favor missed cleavages, gen-
erating larger peptides which are more easily retained
and observed by MALDI than are the hydrophilic
peptide T1 and the more volatile short peptides (e.g.,
T8, T9). However, the N-terminus contains only two of
the known amyloidogenic variants, and reports of ei-
ther are very rare. Studies are underway to improve the
coverage obtained with the method by varying the
experimental parameters such as buffer type, pH, di-
gestion time, temperature, analyte concentration, and
MALDI sample preparation. The method should lend
itself to automation. The minimum amount of patient
serum required for the analysis is not precisely defined
at this point although molecular weight profiles of TTR
were obtained from MALDI using TTR isolated by
immunoprecipitation from 10 mL of patient serum [12].
Defining the minimum amount of serum necessary for
analysis is further complicated by the diminished levels
of TTR found in ATTR patients.
An added feature of this method is its ability to
analyze serum samples from sample banks when whole
blood is not available. The absence of DNA obviously
prohibits the use of molecular biology techniques. Thus,
a serum bank of samples from patients believed to
include potential carriers of an amyloidogenic variant
(Val122Ile) [13] is being screened using immunoprecipi-
tation and MALDI bioreactive probes. An example of
the peptide map generated from the bioreactive probe
digest from the immunoprecipitated TTR of a Val122Ile
patient is shown in Figure 2c. Coupled with the char-
acteristic IEF signature [14] of the variant and clinical
data (Val122Ile is a polymorphism in 3.9% of the
African-American population resulting in extensive car-
diomyopathy), the mass spectrometry results offer fur-
ther confirmation of the presence of the Val122Ile
variant. The ability to carry out screening on sample
banks having attached medical histories is a great asset.
Figure 2. MALDI mass spectrum of “on-probe” digests obtained
from TTR immunoprecipitated from the serum of (a) a non-ATTR
individual, (b) a Val30Met ATTR patient, and (c) a Val122Ile ATTR
patient.
Table 1. Tryptic peptides observed by MALDI analysis of an
“on-probe” digest after digestion for 20 min at 45 °C
Peptide Mass (Da)
“Solution”
digest
“On-probe”
digest
T8–9 (71–80) 1268.4 X X
T4 (22–34) 1366.5 X X
T5–6 (35–48) 1522.6 X
T3–4 (16–34) 2021.4 X
a Xa
T10 (81–103) 2451.7 X X
T12–13 (105–127) 2489.9 X X
T11–12 (104–126) 2516.8 X X
T10–11 (81–104) 2607.8 X
T11–13 (104–127) 2646.0 X X
T7–8 (49–76) 3141.4 X X
aNot consistently observed.
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